AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24441951 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble lutein/zeaxanthin 1 % and brilliant blue 0.025 %
Number of subjects: 18
Study 24442098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 6.25 mg/kg orally twice daily
Number of subjects: 7
Study 24442098 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 7
Study 24443249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 0
Study 24443249 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study 24443277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (doses ranging from 100 mg to 2000 mg)
Number of subjects: 477
Study 24443277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 477
Study 24443504 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation with an irrigated-tip contact force-sensing catheter in temperature-controlled mode (temperature limited to 48°C, power to 30 W)
Number of subjects: 15
Study 24444305 — intervention group
Group type: EXPERIMENTAL
Intervention: B27+ media
Number of subjects: 0
Study 24444305 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous human serum (aHS) and two different commercially available GMP AB HSs
Number of subjects: 0
Study 24444305 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP gamma-irradiated FBSs (giFBSs)
Number of subjects: 0
Study 24444305 — intervention group
Group type: EXPERIMENTAL
Intervention: B27 and selected giFBS
Number of subjects: 0
Study 24444339 — intervention group
Group type: COMPARATOR
Intervention: Presence of at least 1 Ala-MnSOD allele (rs4880) in male subjects
Number of subjects: 110
Study 24444339 — intervention group
Group type: COMPARATOR
Intervention: Presence of 2 G-eNOS allele (rs1799983) in both men and women
Number of subjects: 110
Study 24444526 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral epigallocatechin-3-gallate (EGCG) administered three times a day after the occurrence of grade 2 esophagitis, with dose escalation at six concentration levels.
Number of subjects: 24
Study 24444526 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral epigallocatechin-3-gallate (EGCG) administered three times a day after the occurrence of grade 2 esophagitis.
Number of subjects: 24
Study 24444527 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised isotoxic accelerated radiotherapy (INDAR) with concurrent or sequential platinum-based chemotherapy.
Number of subjects: 83
Study 24445082 — intervention group
Group type: EXPERIMENTAL
Intervention: WELCH questionnaire score
Number of subjects: 450
Study 24445082 — intervention group
Group type: EXPERIMENTAL
Intervention: WELCH questionnaire
Number of subjects: 450
Study 24445353 — intervention group
Group type: EXPERIMENTAL
Intervention: Okada purifying therapy (OPT), administered every weekday for 1 year by certified practitioners.
Number of subjects: 20
Study 24445353 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular patients at the clinic).
Number of subjects: 20
Study 24445353 — intervention group
Group type: EXPERIMENTAL
Intervention: Okada purifying therapy (OPT).
Number of subjects: 20
Study 24445353 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey for those who continued using OPT regularly.
Number of subjects: 20
Study 24445595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hemithoracic intensity-modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP)
Number of subjects: 25
Study 24446519 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15 stimulation of CD8(+) T cells
Number of subjects: 0
Study 24446519 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS or HIV-1-activated dendritic cells (DCs)
Number of subjects: 0
Study 24446519 — intervention group
Group type: EXPERIMENTAL
Intervention: DCs isolated from viremic HIV-1 patients
Number of subjects: 0
Study 24446519 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CD8(+) T cells to CD4(+) T cells
Number of subjects: 0
Study 24446656 — intervention group
Group type: EXPERIMENTAL
Intervention: GIPR Glu354Gln (rs1800437) carriers (C allele)
Number of subjects: 1686
Study 24446656 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the variant C allele
Number of subjects: 1686
Study 24446658 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) serum levels
Number of subjects: 1097
Study 24447083 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of inhaled glucocorticosteroids (1700 μg)
Number of subjects: 169
Study 24447083 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of oral glucocorticosteroids (6.7 mg)
Number of subjects: 169
Study 24447083 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sputum eosinophils (25.7%)
Number of subjects: 169
Study 24447083 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled NO > 45 p.p.b.
Number of subjects: 169
Study 24447083 — intervention group
Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 169
Study 24447458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-protective lung ventilation strategies during ECMO
Number of subjects: 0
Study 24447458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation settings during ECMO
Number of subjects: 0
Study 24447458 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway pressure considerations during venoarterial ECMO support
Number of subjects: 0
Study 24448848 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention targeting high-risk prescribing of NSAIDs and antiplatelets
Number of subjects: 4
Study 24448848 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention targeting asthma control
Number of subjects: 4
Study 24448848 — intervention group
Group type: EXPERIMENTAL
Intervention: DQIP intervention targeting antithrombotics in atrial fibrillation (AF)
Number of subjects: 4
Study 24449032 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal intervention strategy
Number of subjects: 6066
Study 24449167 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrins with glutamine (0.117 g kg(-1) h(-1))
Number of subjects: 5
Study 24449167 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrins alone (0.25 g kg(-1) h(-1), control)
Number of subjects: 5
Study 24449368 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD
Number of subjects: 2315
Study 24449368 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2315
Study 24449716 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy post-fibrinolysis with GPIIb/IIIa inhibitors
Number of subjects: 1059
Study 24449716 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy post-fibrinolysis without GPIIb/IIIa inhibitors
Number of subjects: 1059
Study 24449716 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy post-fibrinolysis with GPIIb/IIIa inhibitors
Number of subjects: 1059
Study 24449716 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy post-fibrinolysis without GPIIb/IIIa inhibitors
Number of subjects: 1059
Study 24450444 — intervention group
Group type: EXPERIMENTAL
Intervention: Early response to treatment (TCS ≤4 days)
Number of subjects: 585
Study 24450444 — intervention group
Group type: COMPARATOR
Intervention: Later response to treatment (TCS >4 days)
Number of subjects: 585
Study 24452648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Group (PG)
Number of subjects: 343
Study 24452648 — intervention group
Group type: COMPARATOR
Intervention: Surgical Group (SG)
Number of subjects: 343
Study 24452648 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid analgesics (NSAIDs) in Pain Group (PG)
Number of subjects: 343
Study 24452648 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid analgesics (NSAIDs) in Surgical Group (SG)
Number of subjects: 343
Study 24452648 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drugs in Pain Group (PG)
Number of subjects: 343
Study 24452648 — intervention group
Group type: COMPARATOR
Intervention: Other drugs in Surgical Group (SG)
Number of subjects: 343
Study 24452648 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs in Pain Group (PG)
Number of subjects: 343
Study 24452648 — intervention group
Group type: COMPARATOR
Intervention: Psychotropic drugs in Surgical Group (SG)
Number of subjects: 343
Study 24452726 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of two Glaukos Trabecular Micro-Bypass iStent inject devices
Number of subjects: 99
Study 24452746 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily for 14 days followed by a single dose of colchicine 0.6 mg co-administered with atorvastatin 40 mg
Number of subjects: 24
Study 24452746 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of colchicine 0.6 mg
Number of subjects: 24
Study 24452753 — intervention group
Group type: EXPERIMENTAL
Intervention: R2
Number of subjects: 51
Study 24452753 — intervention group
Group type: EXPERIMENTAL
Intervention: R2*
Number of subjects: 51
Study 24452753 — intervention group
Group type: COMPARATOR
Intervention: R2 and R2*
Number of subjects: 51
Study 24455219 — intervention group
Group type: EXPERIMENTAL
Intervention: Second 200,000 IU capsule of vitamin A
Number of subjects: 276
Study 24455219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 24455219 — intervention group
Group type: EXPERIMENTAL
Intervention: Base retinol level
Number of subjects: 276
Study 24455283 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncotype DX testing
Number of subjects: 225
Study 24455283 — intervention group
Group type: COMPARATOR
Intervention: Tertiary referral centers
Number of subjects: 225
Study 24455283 — intervention group
Group type: COMPARATOR
Intervention: Municipal hospital treatment
Number of subjects: 225
Study 24455735 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with ultracaine
Number of subjects: 111
Study 24455735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (2 puffs on cervical mucosa)
Number of subjects: 111
Study 24455735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexketoprofen trometamol (25 mg)
Number of subjects: 111
Study 24455735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1000 mg)
Number of subjects: 111
Study 24455735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 111
Study 24456220 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antenatal melatonin administration via intravenous infusion until term
Number of subjects: 0
Study 24456220 — intervention group
Group type: COMPARATOR
Intervention: IUGR alone (control group)
Number of subjects: 0
Study 24456358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanthocyanins from black soybean extract
Number of subjects: 0
Study 24456586 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 14 mg/m2 as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days for up to 6 cycles; patients with response or stable disease could continue beyond 6 cycles.
Number of subjects: 130
Study 24456695 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT score category 0-9
Number of subjects: 0
Study 24456695 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT score category 10-19
Number of subjects: 0
Study 24456695 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT score category 20-29
Number of subjects: 0
Study 24456695 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT score category 30-40
Number of subjects: 0
Study 24456695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation history (≥2 vs. 1 event in the past year)
Number of subjects: 0
Study 24456794 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2584702 (50-200mg) + erlotinib (150mg once daily)
Number of subjects: 29
Study 24456794 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2584702 (50-200mg) + everolimus (10mg once daily)
Number of subjects: 29
Study 24457244 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK525762 (a novel, orally bioavailable bromodomain and extra terminal inhibitor)
Number of subjects: 1
Study 24457244 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin, ifosfamide, and etoposide
Number of subjects: 1
Study 24457280 — intervention group
Group type: EXPERIMENTAL
Intervention: Women undergoing primary PCI
Number of subjects: 8073
Study 24457280 — intervention group
Group type: COMPARATOR
Intervention: Men undergoing primary PCI
Number of subjects: 8073
Study 24457377 — intervention group
Group type: EXPERIMENTAL
Intervention: Src inhibition
Number of subjects: 0
Study 24457379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (840-mg loading dose and 420-mg maintenance intravenously every 3 weeks) and erlotinib (150-mg or 100-mg dose orally, daily)
Number of subjects: 41
Study 24457379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab and erlotinib
Number of subjects: 41
Study 24457423 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai-Five Minute Hearing Test (Thai-FMHT)
Number of subjects: 558
Study 24458353 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment (bedtimes delayed by 8.5 h on 4 of the 8 days)
Number of subjects: 26
Study 24458353 — intervention group
Group type: COMPARATOR
Intervention: Circadian alignment (fixed nocturnal bedtimes)
Number of subjects: 26
Study 24458437 — intervention group
Group type: EXPERIMENTAL
Intervention: VcR-CVAD induction chemoimmunotherapy
Number of subjects: 75
Study 24458437 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (MR)
Number of subjects: 75
Study 24458437 — intervention group
Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 75
Study 24458953 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-FDG uptake (measured by target-to-background ratio, TBR)
Number of subjects: 130
Study 24458953 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid wall area (WA) changes
Number of subjects: 130
Study 24458953 — intervention group
Group type: EXPERIMENTAL
Intervention: Total vessel area (TVA) changes
Number of subjects: 130
Study 24459159 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported autoimmune disease
Number of subjects: 0
Study 24459219 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa and reduced-dose CYC
Number of subjects: 6
Study 24459612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 22
Study 24459612 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 22
Study 24460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 6610
Study 24460974 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of smoking cessation guidelines (5 A's framework)
Number of subjects: 30
Study 24460974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation counseling by emergency nurses (ENs)
Number of subjects: 30
Study 24460974 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perceptions of cessation counseling in the ED
Number of subjects: 30
Study 24460975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (15 ml) deposited above the femoral nerve (Group A)
Number of subjects: 52
Study 24460975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (15 ml) deposited below the femoral nerve (Group B)
Number of subjects: 52
Study 24460975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (15 ml) deposited circumferential to the femoral nerve (Group C)
Number of subjects: 52
Study 24461472 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <-2 SDS (moderate malnutrition)
Number of subjects: 2567
Study 24461472 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <-3 SDS (severe malnutrition)
Number of subjects: 2567
Study 24461472 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <-2 SDS
Number of subjects: 2567
Study 24461715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweden
Number of subjects: 510863
Study 24461715 — intervention group
Group type: COMPARATOR
Intervention: UK
Number of subjects: 510863
Study 24461715 — intervention group
Group type: COMPARATOR
Intervention: UK vs Sweden
Number of subjects: 510863
Study 24461715 — intervention group
Group type: COMPARATOR
Intervention: UK vs Sweden over time
Number of subjects: 510863
Study 24462117 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified RESIDential Environment physical activity questionnaire
Number of subjects: 152
Study 24462171 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE) guided biopsy
Number of subjects: 22
Study 24463454 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg) single dose
Number of subjects: 66
Study 24463454 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg) chronic treatment
Number of subjects: 66
Study 24464121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized hyaluronic acid gel (HA)
Number of subjects: 61
Study 24464355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 27
Study 24464355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg/day on day 1 followed by 800 mg/day from day 2 onward
Number of subjects: 27
Study 24464355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 1,000 mg/day
Number of subjects: 27
Study 24464355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus lapatinib (400/1,000 mg, 800/1,000 mg, 400/1,500 mg, 600/1,250 mg)
Number of subjects: 27
Study 24464355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib monotherapy (800 mg and 1,000 mg) and pazopanib plus lapatinib (any doses)
Number of subjects: 27
Study 24464597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 85
Study 24464944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained blood oxygenation level-dependent responses in the superior temporal sulcus (STS) while observing facial expressions.
Number of subjects: 0
Study 24464944 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related changes in sustained MEG beta-band (14-30 Hz) oscillatory activity in the STS.
Number of subjects: 0
Study 24464944 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient beta-band activity in sensorimotor cortex during viewing of fearful and happy expressions.
Number of subjects: 0
Study 24464944 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sustained STS beta-band activity with speed of emotion recognition.
Number of subjects: 0
Study 24464944 — intervention group
Group type: EXPERIMENTAL
Intervention: Valence-specific coupling of STS beta-band activity with facial movements.
Number of subjects: 0
Study 24465046 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 µg sufentanil plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Number of subjects: 93
Study 24465046 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg fentanyl plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Number of subjects: 93
Study 24465046 — intervention group
Group type: COMPARATOR
Intervention: 0.5% levobupivacaine (2.2 ± 0.2 mL)
Number of subjects: 93
Study 24465370 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for symptom scores
Number of subjects: 292
Study 24465370 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe headache
Number of subjects: 292
Study 24465370 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of symptoms
Number of subjects: 292
Study 24465444 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) with HIV-positive Peer Mentors; 4 antenatal and 4 postnatal meetings
Number of subjects: 1200
Study 24465444 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1200
Study 24465572 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 812
Study 24465572 — intervention group
Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 812
Study 24465572 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid culture
Number of subjects: 812
Study 24465663 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for measuring retinal nerve fiber layer (RNFL) thickness in PD patients
Number of subjects: 644
Study 24465663 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for measuring RNFL thickness in PD patients
Number of subjects: 644
Study 24467603 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in the prostaglandin E2 pathway
Number of subjects: 680
Study 24467603 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4434423A in the PTGER4 gene
Number of subjects: 680
Study 24467608 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Number of subjects: 206
Study 24467608 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer surgical procedures
Number of subjects: 206
Study 24467608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain incidence
Number of subjects: 206
Study 24467767 — intervention group
Group type: EXPERIMENTAL
Intervention: CuidaCare intervention (standard care intervention in primary health care)
Number of subjects: 142
Study 24467767 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without CuidaCare intervention)
Number of subjects: 142
Study 24467767 — intervention group
Group type: EXPERIMENTAL
Intervention: CuidaCare intervention
Number of subjects: 142
Study 24467979 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 treatment
Number of subjects: 0
Study 24467979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24467987 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool substitute preparation made from purified intestinal bacterial cultures derived from a single healthy donor
Number of subjects: 2
Study 24467987 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool substitute preparation
Number of subjects: 2
Study 24469387 — intervention group
Group type: EXPERIMENTAL
Intervention: ELOPE Study (Evaluation of Long-term Outcomes after Pulmonary Embolism)
Number of subjects: 0
Study 24469387 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual pulmonary vascular abnormalities on follow-up imaging and echocardiogram
Number of subjects: 0
Study 24469387 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial and/or residual clot burden, recurrent pulmonary embolism, altered pulmonary artery or right ventricular hemodynamics, or other prognostic factors such as biomarker levels
Number of subjects: 0